Study to examine the efficacy and safety of Awa Suzuka extracted ingredients

Phase II study to examine the efficacy and safety of Awa Suzuka extracted ingredients - Phase II study of Awa Suzuka extracted ingredients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052759

Enrollment

Registered

2023-11-10

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects with serum triglyceride levels in the borderline range

Interventions

Specifics of the intervention act (4 tablets/day of tabletized powder, administration period of 30 days) Criteria for implementation of the intervention

ingestion after breakfast Criteria for modification of the intervention

discontinuation of the intervention if any discomfort (diarrhea or other gastrointestinal symptoms, mood disorder, allergic symptoms, etc.) occurs due to ingestion Criteria for discontinuation or com

discontinuation if any intake-related discomfort (diarrhea or other gastrointestinal symptoms, dysphoria, allergic symptoms, etc.) occurs Specifics of the intervention act (4 tablets/day of tabletized

discontinuation if any intake-related discomfort (diarrhea or other gastrointestinal symptoms, dysphoria, allergic symptoms, etc.) occurs

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: People with triglyceride levels in the 120-149 mg/dL range

Exclusion criteria

Exclusion criteria: Persons with diseases of the liver, kidney, heart, etc. Those who are taking medication for the purpose of treatment of diseases such as lifestyle-related diseases Those who have taken supplements within 1 month of the start of the study

Design outcomes

Primary

Measure	Time frame
Serum triglyceride level	—

Secondary

Measure	Time frame
Body Fat Percentage body weight	—

Countries

Japan

Contacts

Public ContactHirohshi Sakaue

Tokushima University Graduate Schoo Institute of Biomedical sciences

hsakaue@tokushima-u.ac.jp0886339249

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026